Johnson & Johnson: UE approves Darzalex for multiple myeloma
(CercleFinance.com) - The European Commission has approved a drug to be sold by Johnson & Johnson's Janssen as a treatment for a form of blood cancer.
Brussels has granted marketing authorisation for Darzalex (daratumumab) for use as initial therapy in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
In a Phase 3 study, Daratumumab reduced the risk of disease progression or death by 50%, compared to treatment with bortezomib, melphalan and prednisone alone.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Brussels has granted marketing authorisation for Darzalex (daratumumab) for use as initial therapy in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
In a Phase 3 study, Daratumumab reduced the risk of disease progression or death by 50%, compared to treatment with bortezomib, melphalan and prednisone alone.
Copyright (c) 2018 CercleFinance.com. All rights reserved.